Implantation of phakic intraocular lenses (IOLs) has many advantages over keratorefractive procedures such as laser-assisted in situ keratomileusis (LASIK). In the treatment of high-degree myopia by LASIK, relatively large amounts of cornea must be ablated, small effective optical zones are created and the predictability and stability of the procedure begin to diminish. 1, 2 Furthermore, many refractive surgeons have reconsidered the assumption that an alteration of the natural corneal shape is the best way to address myopic and astigmatic refractive errors based on a number of factors, including a better understanding of the biomechanical effect of LASIK on the cornea (especially in severe cases of myopia), the increasing number of reported corneal ectasia cases after LASIK and the development of sophisticated wavefront analysers that objectively measure the negative effect of LASIK on quality of vision (especially in relation to surgically induced high-order aberrations). 3 The potential removability and exchangeability of phakic IOL implantation is generally absent in keratorefractive procedures. Co-existing astigmatism can be neutralised at the time of the surgery by varying the incision through which the lens is implanted or by the use of toric phakic 
Implantable Contact Lens
Implantable contact lenses (ICLs) are phakic posterior chamber lenses manufactured by Staar Surgical (Nidau, Switzerland). They use a single-piece plate-haptic lens designed to anteriorly vault to the crystalline lens and intended to have minimal contact with the natural lens. The lens material is a proprietary hydrophilic collagen polymer -a co-polymer of 63% hydroxyethyl-methyl-acrylate, 0.2% collagen and 3.4% a benzofenone for ultraviolet (UV) absorption -known as Collamer ® , with a water content of 34%, light transmission properties of 99% and a refractive index of 1.45 at 35ºC. Three versions of ICL are currently available. 6 The myopic version of the ICL (V4 version) is plano-concave, with the anterior surface being plano; the optic diameter ranges from 4.65 to 5.50mm. The thickness of the lens is less than 50µm at the centre of the optic and less than 100µm at the haptic plate. The thickest part of the myopic ICL is the junction between the optic and the haptic and ranges from 300 to 700µm. The overall length of myopic ICL ranges from 11.5 to 13mm in 0.5mm increments. Power ranges from -23.00 to -3.00 diopters (D) in half-D increments. [6] [7] [8] [9] [10] The hyperopic ICL (V3 version) is concave-convex, with the anterior surface being convex. The optic diameter is fixed at 5.5mm for all powers, and the thickest part is the centre of the optic. Overall lengths of hyperopic ICLs range from 11 to 12.5mm in 0.5mm increments. Power ranges from +3.00 to +21.50 D in half-D increments. 6, 10 The toric ICL (V4 version) has a toric convex-concave optic that incorporates the desired cylindrical power in a specific axis as required to correct a given patient's astigmatic condition. It is manufactured using the platform of the non-toric design and is similar to the spherical ICL in terms of size, thickness and configuration, with the addition of a toric optic to correct myopia with astigmatism. To minimise the rotation required by the surgeon during implantation, the toric ICL is custom-made to be implanted on the horizontal axis. The time from order to delivery for a toric ICL is between four and six weeks; to shorten this time, the surgeon has the option of using a ready-made toric ICL of the same required power with a cylinder axis within 22.5°of the power needed. In such cases, the 'alternative' toric ICL will have to be rotated inside the eye to compensate for the difference in axis orientation. Each toric ICL is sent to the surgeon with a guide that demonstrates the amount and direction of rotation from the horizontal axis required to align the toric ICL cylinder axis to correct the patient's astigmatism. It is recommended that rotation is less than 22.5°f rom the horizontal. The cylindrical power ranges from 1.0 to 6.0D with the same range of spherical power as the myopic ICL. 6, 11, 12 The myopic ICL (V4 version) was approved by the US Food and Drug 
Implantable Contact Lenses versus Laser-assisted

In Situ Keratomileusis -Clinical Studies
Myopic Correction
Various clinical studies were designed to compare the ICL with LASIK (or other keratorefractive techniques) in terms of refractive correction.
Advantages of Implantable Contact Lenses Over
Laser-assisted In Situ Keratomileusis Post-operative refraction stability was also better with the ICL, while continuous regression was evident in the LASIK group. 20 The same authors also demonstrated higher efficiency and safety after ICL implantation during the entire follow-up period, and higher subjective patient satisfaction was determined, using a questionnaire, in the ICL group. 21 
Astigmatic Correction
